Fortrea oncology: Large enough to serve in the UK, engaged enough to care

Over the past decade, there has been remarkable progress in oncology, driven by a deeper understanding of cancer biology and the integration of cutting-edge technologies. Agile biotech companies have played a crucial role in these innovations. Flexibility, speed and focus on scientific advancements have allowed potential new treatments to move rapidly from research to clinical trials. This has been especially impactful when it comes to experimental treatments and leveraging new platforms like biomarkers for precision medicine, artificial intelligence and gene editing (e.g., CRISPR).

Innovative Contract Research Organizations (CROs) such as Fortrea have evolved significantly to meet the unique demands of biotech companies, especially as the landscape in oncology continues to shift. At Fortrea, **75% of our oncology clients are biotech companies,** dynamic in their priorities and strategy, with a strong core team that is focused on making fast decisions and delivering value. As agile biotech companies push the boundaries of innovation, we have evolved to become true partners rather than just considered as service providers. Fortrea aspires to be your oncology-focused CRO of choice. With a steadfast commitment to understanding and exceeding your needs and expectations, we recognize the growing complexity in clinical trial planning and delivery. In today's fast-paced environment, where swift decision-making is crucial, you need a **trusted, clinically focused partner with the experience and expertise** to help navigate these challenges and drive results.

Fortrea

With over 30 years of presence in the UK, beginning as Covance, merging with Chiltern and now becoming Fortrea, an end-to-end clinically-focused drug development organization. With **over 2,000 research professionals** dedicated to clinical research in the UK focused on clinical trial design, setup and operational delivery, regulatory advice and interface, pre-clinical services, and drug development consulting, **we are here to serve you.** We fully understand the expectations of the Medicines and Healthcare products Regulatory Agency (MHRA) regarding early engagement and study approvals.

Leveraging our established relationships with most leading UK cancer centres, along with our strong relationships with networks like the National Institute for Health and Care Research (NIHR) and specifically the Experimental Cancer Medicine Centres Network (ECMC), we are well-positioned to accelerate the clinical trial process. Several leading oncology centres in the UK are also part of Fortrea's global Early Phase Oncology Network (EPON). By collaborating closely with these organizations, we can streamline start-up timelines, enhance patient engagement and focus on efficient recruitment, leading to faster and more effective progression of oncology research.

As the number of oncology assets being considered for First-in-Human (FIH) studies in healthy volunteers continues to rise, purpose-built clinical pharmacology services such as the Fortrea Clinical Research Unit-Phase 1 at Leeds play a crucial role in this evolving landscape. These studies serve as the foundation for transitioning treatments into cancer patient populations. By engaging with renowned oncology centres and networks such as the ECMC in the UK, we can seamlessly move from early-phase trials to pre- and post-registrational phases. This integrated approach provides quality, accelerates timelines and simplifies the complexities you face, all while delivering the insights needed to advance oncology treatments with confidence.



Our extensive network of highly qualified oncology sites, including UK sites within EPON, enables us to collaborate with engaged sites that possess the specialized expertise and access to the appropriate patient populations required for a diverse range of current studies.

Key advantages of running your trial in the UK include:

- **High scientific and study engagement:** UK oncology investigators are renowned for their expertise, dedication and leadership in clinical trials. With a deep understanding of cutting-edge research and patient care, they are highly skilled in delivering high-quality, efficient studies
- **Speed:** Improved efficiency in regulatory processes, from FIH to registrational approval
- **MHRA interaction:** Advantage of single submission includes saving you time and money
- **Financial:** Attractive R&D tax incentives, especially for Small and Mid-size Enterprises (SMEs)
- **Quality:** Deep experience, capabilities and quality management culture
- **Subject population:** Culturally and genetically diverse and geographically centralized high-density patient populations, accommodating referrals through a unified healthcare system. An informed patient population, resulting in a higher level of clinical trial participation willingness

Our **global clinical services experience in Oncology** represents:

- 573 studies
- 4,835 institutions
- 138,000 cancer patients

LEARN MORE at fortrea.com

Fortrea